Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Adenine
/ analogs & derivatives
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Dexamethasone
/ administration & dosage
Drug Resistance, Neoplasm
/ drug effects
Female
Follow-Up Studies
Humans
Male
Middle Aged
Multiple Myeloma
/ drug therapy
Neoplasm Recurrence, Local
/ drug therapy
Oligopeptides
/ administration & dosage
Piperidines
Prognosis
Pyrazoles
/ administration & dosage
Pyrimidines
/ administration & dosage
Salvage Therapy
Survival Rate
Bruton's tyrosine kinase inhibitor
carfilzomib
ibrutinib
multiple myeloma
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
20
12
2019
revised:
31
01
2020
accepted:
08
02
2020
pubmed:
14
2
2020
medline:
1
9
2020
entrez:
14
2
2020
Statut:
ppublish
Résumé
Patients with multiple myeloma (MM) inevitably relapse on initial treatment regimens, and novel combination therapies are needed. Ibrutinib is a first-in-class, once-daily inhibitor of Bruton's tyrosine kinase, an enzyme implicated in growth and survival of MM cells. Preclinical data suggest supra-additivity or synergy between ibrutinib and proteasome inhibitors (PIs) against MM. This phase 1/2b study evaluated the efficacy and safety of ibrutinib plus the PI carfilzomib and dexamethasone in patients with relapsed/refractory MM (RRMM). In this final analysis, we report results in patients who received the recommended phase 2 dose (RP2D; ibrutinib 840 mg and carfilzomib 36 mg/m
Identifiants
pubmed: 32053229
doi: 10.1002/hon.2723
pmc: PMC7496325
doi:
Substances chimiques
Oligopeptides
0
Piperidines
0
Pyrazoles
0
Pyrimidines
0
ibrutinib
1X70OSD4VX
carfilzomib
72X6E3J5AR
Dexamethasone
7S5I7G3JQL
Adenine
JAC85A2161
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
353-362Subventions
Organisme : Pharmacyclics LLC, an AbbVie Company
ID : No grant or award number
Informations de copyright
© 2020 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.
Références
Leukemia. 2012 Jan;26(1):149-57
pubmed: 21799510
Haematologica. 2011 Feb;96(2):333-6
pubmed: 20952514
Cancer Treat Rev. 2012 Dec;38(8):968-80
pubmed: 22226939
Blood Cancer J. 2019 Mar 7;9(3):32
pubmed: 30846679
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
Br J Haematol. 2018 Aug;182(4):504-512
pubmed: 29873072
Clin Cancer Res. 2011 May 1;17(9):2734-43
pubmed: 21364033
Lancet Oncol. 2016 Jan;17(1):27-38
pubmed: 26671818
Ann N Y Acad Sci. 2006 Apr;1068:319-26
pubmed: 16831932
Blood. 2011 May 5;117(18):4691-5
pubmed: 21292775
Curr Oncol. 2014 Aug;21(4):e573-603
pubmed: 25089109
Leukemia. 2017 Nov;31(11):2443-2448
pubmed: 28620163
Blood. 2012 Aug 30;120(9):1877-87
pubmed: 22689860
Curr Opin Hematol. 2016 Jul;23(4):426-33
pubmed: 27101529
Cancer Treat Rev. 2018 Nov;70:199-208
pubmed: 30245231
Curr Hematol Malig Rep. 2017 Apr;12(2):96-108
pubmed: 28317082
Cancer Metastasis Rev. 2017 Dec;36(4):561-584
pubmed: 29196868
PLoS One. 2013 Sep 16;8(9):e74191
pubmed: 24066119
Expert Rev Hematol. 2018 Nov;11(11):863-879
pubmed: 30334460
Drugs R D. 2019 Jun;19(2):73-92
pubmed: 30993606
Br J Haematol. 2012 Sep;158(6):739-48
pubmed: 22845873
Haematologica. 2018 Dec;103(12):2079-2087
pubmed: 30237264
Hematol Oncol. 2020 Aug;38(3):353-362
pubmed: 32053229
Jpn J Clin Oncol. 2018 Sep 1;48(9):785-793
pubmed: 30102324
Cell Signal. 2013 Jan;25(1):106-12
pubmed: 22975686
Leuk Lymphoma. 2018 Nov;59(11):2588-2594
pubmed: 29616843
Eur J Cancer Care (Engl). 2017 Nov;26(6):
pubmed: 28940410
Br J Haematol. 2018 Mar;180(6):821-830
pubmed: 29435979